Biotech Talent Market Sees No 'Golden March, Silver April' in 2026: Industry Rationalization Reshapes Hiring Landscape

This spring, the biotech industry’s traditional “Golden March and Silver April” hiring season seemed to fail to materialize:Companies and candidates size each other up, yet mutual alignment is rarely achieved.

On one hand, job seekers are finding it increasingly difficult to secure employment. “It took me several months to finally land a job. Indeed, there are very few positions open to fresh graduates in the biotech sector this year.” “Several companies that were highly sought-after previously made it easy for me to receive offers during my interviews last year, but I’ve heard that things have become much more challenging this year.” On the other hand, many companies have job vacancies that remain unfilled for extended periods.

Chinese Biotech firms stand at a watershed moment between the 2.0 and 3.0 eras, with talent emerging as the key to breakthroughs; indeed, the flow of talent is reshaping the industry’s landscape. Executive search consultants are among those with the clearest view of this evolving map, as they maintain close contact with candidates while also engaging with various business units (BUs) and even founders of Biotech companies. Moreover, many Biotech-focused recruiters come from pharmaceutical or life sciences backgrounds themselves.

What Exactly Happened in the Biotech Industry This Job-Seeking Season? We Attempt to Gauge the Hiring Market’s Vitality, Supply and Demand for Positions, Salary Adjustments, and, More Importantly, Shifts in Industry Trends, Based on Insights from Several Senior Headhunters Specializing in Biopharmaceuticals.

“From my perspective, the ‘Golden March and Silver April’ recruitment season has cooled significantly. Large companies are cutting projects and reducing headcount; small and mid-sized biotech firms are facing financing difficulties, and those engaged in original research still have a long way to go before reaching clinical stages. Many job seekers this year are making passive choices,” said Liu Huan, a headhunter specializing in clinical development, describing the tone of this year’s hiring season.

Recently, Fierce Biotech released its compiled layoff data for the first quarter of 2023, revealing that 56 biopharmaceutical companies in the U.S. market implemented layoffs, representing an 87% increase compared to the same period in 2022. Although no statistical data are available for the Chinese market, industry participants have likewise felt the chill.

Biotech operations have always relied on market funding. Although many positive signals have emerged in China this year—including a rebound in the secondary market and a steady stream of major licensing deals—many companies still face cash flow challenges. Consequently, they are curbing early-stage R&D investment, freezing headcount, or even downsizing to ensure the advancement of key projects.

Some candidates are seeking new opportunities because their previous companies canceled projects, while others, seeing no prospects for promotion or salary increases—or being informed that annual salary adjustments had been cancelled—were driven by a sense of crisis to explore the job market.

However, exploring opportunities does not equate to changing jobs. On one hand, an increasing number of companies are cautious about candidates who frequently change jobs. In the past, candidates who changed jobs every three years were considered very stable, and those who changed jobs every one to two years were quite common. As the market becomes more rational, companies now expect longer intervals between job changes.

“It generally takes two to three years to complete a project; individuals who change jobs too frequently are unable to see a project through from start to finish. This may be overlooked during periods of severe talent shortage in the industry, but when the market returns to rationality, such candidates may face salary reductions or even find themselves eliminated from consideration,” said a senior pharmaceutical headhunter.

Biotech’s hiring decision cycle has also become significantly longer than in the past., some companies repeatedly compare candidates’ qualifications or continuously adjust the job description (JD) to find a better fit and reduce the cost of trial and error.

On the other hand, “seeking stability” and “playing it safe” have become the prevailing mindset among most candidates. They are taking a more cautious approach to their careers, no longer overly pursuing high salaries or cutting-edge fields, nor are they easily swayed by grandiose capital-driven visions. In some job-hunting discussions, job seekers remind each other:Select companies with core technologies, not just those in hot sectors., exercise caution with companies that have very little public information, lack core publications or patents, and whose representatives make extravagant claims during interviews that preclude in-depth due diligence.

“Candidates are willing to engage in discussions when promising opportunities arise, but they exercise extreme caution when making job-switching decisions—unless their current team or company is truly at a critical juncture of survival.” This observation was confirmed by a headhunter who has served early-stage biotech firms and Chapter 18A-listed biotech companies for many years.

The biopharmaceutical industry is a field that attracts high-quality talent. In an environment of supply-demand imbalance, the gathering of outstanding individuals makes “involution” inevitable.

“To be honest, there are not many good positions available now, and companies have significantly raised their requirements for candidates.” A headhunter explained that, taking the position of R&D Director as an example, specific candidate profiles include: having worked as a physician, with experience in basic or translational medical research; possessing experience at large enterprises, having managed clinical development teams, and even having built teams from scratch (from 0 to 1) and scaled them up (to 10); expertise spanning two to three therapeutic areas, with familiarity in the entire R&D process and Good Clinical Practice (GCP); and a track record of successful early-stage R&D, preferably with projects advanced to Investigational New Drug (IND) application stage, along with experience and resources in regulatory submissions.

The underlying reasons are as follows:It reflects the biotech industry’s heightened expectations for new-generation management teams and scientific research leaders during its evolutionary process.。

Karl Zhu, Senior Manager of Hays Shanghai’s Life Sciences team, stated in a previous interview: “Biotech companies initially require R&D talent; as their pipelines advance, they need various commercial operations roles, particularly senior commercial executives who can understand and collaborate with pre-launch departments such as R&D and clinical development.”

A headhunter shared a case he observed in the first quarter: A candidate was recruited by an innovative therapy company due to their exceptional proficiency in liaising with regulatory authorities, receiving an offer nearly twice as high as that of a listed pharmaceutical company.

Many biotech companies have also turned their recruitment efforts overseas, as the supply of high-end talent in early-stage R&D and CMC primarily comes from developed biotech regions such as Europe and the United States. Under the pressure of volume-based procurement, expanding into international markets has become a critical pathway for many companies, prompting biotechs to pay a premium for scarce professionals who are well-versed in overseas regulatory systems and markets.

“Previously, talent mapping was conducted primarily within China; now, we need to source candidates overseas.“A headhunter serving biotech firms in the Yangtze River Delta region told us, ‘These professionals are highly experienced; they can help companies establish global clinical development strategies and facilitate future collaborations with multinational corporations (MNCs).’”

This has intensified competition for the already limited number of promising opportunities. However, Hank Yang, a recruiter specializing in Research & CMC at CGL Consulting, points out that overseas talents carefully weigh various factors when considering returning to China. For instance, some are motivated by the desire to care for their families, while others, after many years working at major U.S. pharmaceutical companies, seek suitable career paths by comparing how well their professional development or entrepreneurial aspirations align with opportunities in the United States versus China. Important influencing factors also include corporate management culture, compensation and benefits packages, and whether sufficient flexibility exists to allow returnees to balance transnational family life.

“Good positions are scarce, and good candidates are even scarcer”—this is the consensus among many headhunters.。“The supply of high-end talent is decreasing., truly talented individuals are highly sought after and fiercely competed for by companies. Meanwhile, local talent is rapidly growing alongside the company’s development and product development processes, soThe Supply of Mid-Level Talent Is Increasing. But some positions have an oversupply, with an overflow of applicants.”

For example, according to statistics from CGL Consulting, biotech companies’ hiring demand in clinical medicine and clinical operations has decreased by more than 50% year-on-year. However, since the clinical sector had previously absorbed a large number of employees, relevant talent seeking opportunities this year have become “hard to afford.” “If professionals in Development do not evolve toward meeting clinical needs and controlling costs,This will inevitably lead to a wave of personnel optimization through natural selection.。”

For a long time, Chinese biotech companies have followed the trajectory of their U.S. counterparts, experiencing similar industry phases: an initial period of vigorous growth, a honeymoon phase with capital, and now a post-euphoria period of bubble deflation. Driven by the pandemic and shifting economic conditions, this downturn arrived much earlier than anticipated.

U.S. biotech companies have largely diverged into two distinct paths through multiple rounds of screening: one is the biopharma model, which has been widely discussed; however, only a select few, such as Moderna, have successfully transitioned into full-fledged pharmaceutical companies. The other path involves maintaining the core characteristics of biotech firms, namely excellence in technological breakthroughs, early-stage research, and translation of scientific achievements.

“Most biotech companies will remain as such, lacking both the intention and capacity to evolve into biopharma firms,” pointed out a headhunter. “Thus, R&D capability is key. Consequently, talent in research—including CMC professionals—will be less affected by market conditions and will continue to see salary increases.”

Another path for U.S. biotech companies is acquisition through M&A; however, China’s M&A market remains immature, lacking the large number of major pharmaceutical companies capable of absorbing biotech assets as seen abroad. In recent years, domestic biotech firms have begun to adopt the U.S. model of collaborative R&D or license-out strategies, thereby securing strong endorsements and cash flow. Data from the first quarter of 2023 shows that the total value of nine disclosed license-out deals for Chinese innovative drugs exceeded $8 billion.

Biotech firms are increasingly active in pursuing licensing deals, driving surging demand for business development (BD) services.

Jiang Xiaoyang, founder of Yafa Capital and a cross-border business development (BD) advisory firm, also stated in an interview with VCBeat’s New Medicine that China’s biopharmaceutical industry is at a BD turning point. While there was previously a surplus of talent specializing in license-in deals, many companies now seek to license their products overseas, yet there is a severe shortage of BD professionals capable of handling license-out transactions. “This is because such transactions involve greater complexity and higher barriers to entry. Of course, some seasoned BD professionals can quickly adapt their roles in response to shifting market demands, engaging in both product in-licensing and out-licensing.”

Cherry Mu, Managing Partner at CGL Consulting, stated, “According to our statistics,Demand for BD talent has increased by more than 30% compared to last year., however, the supply of BD talent remains constrained. Currently, some biotech companies are seeking BD consultants for phased collaborations or recruiting professionals with backgrounds in strategy, legal affairs, or finance to transition into BD roles. Top-tier BD executives are scarce, and competition for talent among companies is intense.”

Cherry Mu, with a clinical background, has been working in executive search for nearly two decades, consistently serving multinational and startup biopharmaceutical companies. She has gained profound insights into the development of the biotech sector and the evolving talent landscape over the past few years.

“The return to rationality in biotech means that companies lacking competitive technologies and pipelines, and failing to address unmet clinical needs, will be gradually weeded out, while the industry’s excesses will be stripped away. This is a normal trajectory for development.”